CELL POPULATIONS HAVING IMMUNOREGULATORY ACTIVITY, METHODS FOR THE PREPARATION AND USES THEREOF
The present invention provides a method for treating rheumatoid arthritis comprising the use of mesenchymal stem cells.
1 - 2 . (canceled)
3 . A method of treating rheumatoid arthritis in a subject, comprising administering a composition comprising mesenchymal stem cells (MSCs) to the subject.
4 . The method according to claim 3 , wherein the rheumatoid arthritis is refractory rheumatoid arthritis.
5 . The method according to claim 3 , wherein the MSCs are adipose tissue derived stromal stem cells (ASCs).
6 . The method according to claim 3 , wherein the MSCs are allogeneic.
7 . The method according to claim 3 , wherein the composition comprises expanded MSCs.
8 . The method according to claim 3 , wherein the composition comprises up to about 4×10 6 cells/kg or about 2 million cells/kg or lower.
9 . The method according to claim 3 , wherein the composition comprises be between about 0.5×10 6 cells/kg to about 2×10 6 cells/kg; or more preferably about 1×10 6 cells/kg to about 2×10 6 cells/kg.
10 . The composition method according to claim 3 , wherein at least about 50% of the MSCs express one or more of the markers CD9, CD10, CD13, CD29, CD44, CD49A, CD51, CD54, CD55, CD58, CD59, CD90 and CD105.
11 . The composition method according to claim 3 , wherein the MSCs are expanded adipose tissue derived stromal stem cells, wherein at least about 50% of the MSCs express CD59 and/or CD90, for example wherein at least 65%, at least 70%, or 65-95%, or 70-90% of the MSCs express CD59 and/or CD90.
12 . The method according to claim 3 , wherein at least about 50% of the MSCs do not express the markers CD11b, CD14, CD15, CD16, CD31, CD34, CD45, CD49f, CD102, CD104, CD106 and CD133.
13 . The method according to claim 3 , wherein the MSCs are characterised in that they:
a) do not express markers specific for antigen-presenting cells (APC);
b) do not express indoleamine 2,3-dioxygenase (IDO) constitutively; and
c) express IDO upon stimulation with interferon-gamma (IFN-γ).
14 . The method according to claim 3 , wherein the MSCs are administered in a pharmaceutically acceptable carrier and/or a diluent.
15 . The composition method according to claim 3 , wherein the MSCs are administered systemically.
16 . The composition, method according claim 3 , wherein the MSCs are administered via the subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intrasynovial, intrasternal, intralymphatic, intrathecal, intralesional, or intracranial route.
17 . The composition method according to claim 3 , wherein the MSCs are administered in conjunction with one or more further therapeutic agents.
18 . The composition method of claim 3 , wherein the subject has refractory rheumatoid arthritis and is intravenously administered a dose of 1 million, 2 million or 4 million expanded Adipose-derived Mesenchymal Stem cells/kg on days 1, 8 and 15.
19 . The method of claim 18 , wherein the subject is refractory to at least one biological treatment, for example any one of the biologicals listed in Table 3.
20 . The method of claim 19 , wherein the at least one biological treatment is a TNF-α inhibitor, optionally Adalimumab (Humira), Certolizumab (Cimzia), Etanercept (Enbrel), Golimumab (Simponi), or Infliximab (Remicade).
21 . The method of claim 18 , wherein the subject is refractory to at least two biological treatments, for example any two of the biologicals listed in Table 3.
22 . The method of claim 3 , wherein the subject is refractory to at least one biological treatment and is intravenously administered a dose of about 0.5×10 6 cells/kg to about 2×10 6 cells/kg, about 1×10 6 cells/kg to about 2×10 6 cells/kg, about 2×10 6 cells/kg or lower, or about 1×10 6 cells/kg, at days 1, 8 and 15, wherein the dose comprises a population of cells comprising expanded adipose tissue derived stromal stem cells, wherein the majority of cells express CD59 and/or CD90, typically wherein expression of CD59 and/or CD90 within the population is greater than 50%, greater than 65%, or greater than 70%, e.g. 65-95%, or 70-90%, for treating rheumatoid arthritis in a subject.